Parataxis Korea, Inc.

A288330

KR7288330004

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 07/04/2026			5-day change	1st Jan Change
416.00 ^KRW	-3.03%		-.--%	-53.57%

07/04	Parataxis Korea, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
07/04	Parataxis Ethereum, Inc. agreed to acquire Parataxis Korea, Inc. for KRW 42.8 billion.	CI

Parataxis, Bridge Biotherapeutics Ink Deal to List Bitcoin Treasury Firm on Korea's KOSDAQ

Published on 06/20/2025 at 04:19 pm IST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Parataxis Korea, Inc.

07/04	Parataxis Korea, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
07/04	Parataxis Ethereum, Inc. agreed to acquire Parataxis Korea, Inc. for KRW 42.8 billion.	CI
06/01	Parataxis Korea Fund IV LLC, a fund managed by Parataxis Capital Management LLC and Parataxis Korea, Inc. completed the acquisition of 47.2% stake in Sinsiway Co., Ltd. from EXEM Co., Ltd., Gwang-Yeol Kim, Jae-Hoon Jeong and Gwang-Yeol Kim.	CI
18/12	Parataxis Korea, Inc. announced that it has received KRW 15.000000484 billion in funding from Parataxis Korea Holdings Llc, Parataxis Holdings LLC	CI
10/12	Parataxis Korea, Inc. announced that it expects to receive KRW 15.000000484 billion in funding from Parataxis Korea Holdings Llc, Parataxis Holdings LLC	CI
01/12	Parataxis Holdings LLC, Parataxis Korea Fund Iii Llc and Parataxis Korea, Inc. and other entered into agreement to acquire 47.21% stake in Sinsiway Co., Ltd. from EXEM Co., Ltd., Gwang-Yeol Kim, Jae-Hoon Jeong and Gwang-Yeol Kim for KRW 26.1 billion.	CI
13/11	Parataxis Korea, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
10/25/10	Parataxis Korea, Inc. announced that it has received KRW 9.99999792 billion in funding from Parataxis Holdings LLC and other investors.	CI
14/25/14	Parataxis Korea, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
01/25/01	Bridge Biotherapeutics, Inc. announced that it has received KRW 25.000000416 billion in funding from Parataxis Holdings LLC	CI
30/25/30	Parataxis Korea Fund I Llc managed by Parataxis Holdings LLC acquired 36.98% stake in Bridge Biotherapeutics, Inc. from Kim Byung, Jung Jung Lee, Jungsoon Lee, Lim Jong-jin, Lee Bok-kyu and others	CI
20/25/20	Parataxis Korea Fund I Llc and Parataxis Holdings LLC entered into a definitive agreement to acquire 36.98% stake in Bridge Biotherapeutics, Inc. from Kim Byung, Jung Jung Lee, Jungsoon Lee, Lim Jong-jin, Lee Bok-kyu and others for KRW 25 billion.	CI
20/25/20	Parataxis, Bridge Biotherapeutics Ink Deal to List Bitcoin Treasury Firm on Korea's KOSDAQ	RE
20/25/20	Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 25.000000416 billion in funding from Parataxis Holdings LLC	CI
14/25/14	Parataxis Korea, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

Parataxis Korea Inc formerly Bridge Biotherapeutics Inc, is a Korea-based company mainly engaged in the development and licensing of drug candidates under development. The Company conducts research and development for indications including idiopathic pulmonary fibrosis, non-small cell lung cancer, and ulcerative colitis.

Employees

Sector

Biotechnology & Medical Research

More about the company